Massive study tests Paxlovid's power to keep COVID patients out of hospital
NCT ID NCT07261085
First seen Dec 10, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This study uses health records from nearly 99,000 adults in Ontario to see if the antiviral drug Paxlovid reduces the risk of severe COVID-19 outcomes like hospitalization or death. Researchers compared people who took Paxlovid with those who did not, tracking their health for up to 60 days. The goal is to understand how effective the treatment is in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.